Multidrug Resistant Bacteria Market Report 2026

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $13.27 billion in 2025 to $14.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to overuse of antibiotics in hospitals, inadequate infection control protocols, slow adoption of rapid diagnostics, limited treatment options for resistant strains, high incidence of bloodstream infections.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $18.77 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing investment in antimicrobial R&D, adoption of AI-driven diagnostic tools, development of precision medicine therapies, government initiatives on AMR containment, expansion of homecare and outpatient infection management services. Major trends in the forecast period include rising prevalence of hospital-acquired infections, increasing antibiotic resistance awareness programs, development of novel antibacterial therapies, growth of point-of-care diagnostic technologies, expansion of home healthcare services.

The rising prevalence of infectious diseases is expected to drive the growth of the multidrug-resistant bacteria market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are particularly concerning in infectious diseases due to their ability to cause infections that are difficult to treat with conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, reducing the effectiveness of commonly used treatments for bacterial infections. For instance, in November 2023, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that the number of tuberculosis patients in the USA increased from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Therefore, the rising prevalence of infectious diseases is fueling growth in the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are focusing on developing innovative drugs and obtaining regulatory approvals to meet the needs of this emerging segment. Approval of drugs targeting multidrug-resistant bacteria is crucial to controlling the spread of antibiotic resistance. For instance, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, received Food and Drug Administration (FDA) approval for Xacduor, a combination antibiotic for treating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by Acinetobacter baumannii, a pathogen that is often difficult to treat. Xacduor combines ceftolozane, a cephalosporin antibiotic, with tedizolid phosphate, a novel oxazolidinone, offering a new option for patients who have not responded to other treatments. It can be administered as an injection that pairs the beta-lactam antibiotic sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing Acinetobacter resistance and enhancing antibiotic efficacy.

In January 2024, Basilea Pharmaceutica Ltd., a Switzerland-based biopharmaceutical company, acquired a preclinical antibiotics program from Spexis AG for up to CHF 2 million (≈ US$ 2.2 million). Through this acquisition, Basilea aims to strengthen its antimicrobial resistance (AMR) pipeline by adding a novel class of Gram-negative antibiotics that directly target multidrug-resistant strains, addressing high-priority unmet medical needs. Spexis AG, a Switzerland-based biotech company, develops outer membrane protein-targeting antibiotics (OMPTA) designed to disrupt lipopolysaccharide transport in Gram-negative bacteria, including multidrug-resistant species.

Major companies operating in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2025. The regions covered in the multidrug resistant bacteria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multidrug resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the multidrug-resistant bacteria market by increasing the cost of imported antibiotics, diagnostic equipment, and biopharmaceutical raw materials. This has impacted hospitals, specialty clinics, and homecare services, particularly in regions like North America and Europe that rely on global supply chains. While tariffs have increased production costs and delayed adoption in some segments, they have also encouraged local manufacturing and innovation in cost-effective antibacterial solutions.

The multidrug resistant bacteria market research report is one of a series of new reports that provides multidrug resistant bacteria market statistics, including multidrug resistant bacteria industry global market size, regional shares, competitors with a multidrug resistant bacteria market share, detailed multidrug resistant bacteria market segments, market trends and opportunities, and any further data you may need to thrive in the multidrug resistant bacteria industry. This multidrug resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple types or classes of antibiotics. These bacteria are no longer affected by several antibiotics that would normally be effective in treating bacterial infections. Multidrug-resistant organisms often emerge in hospitals and healthcare facilities when antibiotics are used for longer than necessary or when they are administered unnecessarily.

The main types of diseases caused by multidrug-resistant bacteria include urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia, and others. A urinary tract infection is an infection that affects any part of the urinary system, including the kidneys, bladder, and ureters. These diseases can be treated with various drugs such as oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and others, administered via oral, parenteral, and other routes. The end users of these treatments include hospitals, specialty clinics, homecare providers, and others.

The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.